Apimeds Pharmaceuticals US (APUS) Profit After Tax (2024 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Profit After Tax came in at -$1.2 million in Q4 2025, down 270.72% YoY from $676709.6 in Q4 2024, and up 35.14% on a QoQ basis from -$1.8 million in Q3 2025.
Apimeds Pharmaceuticals US (APUS) Profit After Tax (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 2 years of Profit After Tax data on file, last reported at -$1.2 million in Q4 2025.
- Quarterly Profit After Tax fell 270.72% year-over-year to -$1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$6.0 million (down 331.74% YoY) and the FY2025 annual result came in at -$6.0 million, down 331.74% from the prior year.
- Profit After Tax improved to -$1.2 million in Q4 2025, from -$1.8 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$296473.0 in Q1 2024 to a low of -$2.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 710.56 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 149.10 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Apimeds Pharmaceuticals US | 7.48 Mn | 7.48 Mn | - | -20.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.16 Mn |
| Sep 30, 2025 | -1.78 Mn |
| Jun 30, 2025 | -2.66 Mn |
| Mar 31, 2025 | -402,397.00 |
| Dec 31, 2024 | -311,633.00 |
| Sep 30, 2024 | -332,521.00 |
| Jun 30, 2024 | -449,363.00 |
| Mar 31, 2024 | -296,473.00 |